Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cgrp Diagnostics GmbH has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, GURLEY, JAMI MICHELLE, who is the busiest examiner for the portfolio with 1 busiest examiner pending action. The activity is limited to 1 distinct art unit, showing a focused approach to patenting in this technical field.
Since the company has only 1 pending office action, the entire prosecution effort is currently directed toward GURLEY, JAMI MICHELLE. This allows the applicant to tailor their arguments specifically to one examiner's perspective within the Biotechnology & Pharmaceuticals sector. The 1 distinct examiner involved is the sole point of contact for the company's current active matters at the patent office.
The use of 1 distinct art unit indicates that the technology is being evaluated within a specific division of the patent office. With 1 busiest examiner pending action to manage, the company's legal team can focus on the specific prior art and legal issues raised by GURLEY, JAMI MICHELLE. This streamlined prosecution environment is efficient but places high importance on the outcome of this single office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GURLEY, JAMI MICHELLE | 1 | 54.8% | +14.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294553 | PREVENTATIVE TREATMENT OF MIGRAINE | GURLEY, JAMI MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294553 | PREVENTATIVE TREATMENT OF MIGRAINE | GURLEY, JAMI MICHELLE | 1647 | §103 | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCgrp Diagnostics GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jami Michelle Gurley has the most, with 1 of Cgrp Diagnostics GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
